Pfizer and Opko end 2016 downbeat as hGH-CTP fails phase 3 – FierceBiotech
FierceBiotech |
Pfizer and Opko end 2016 downbeat as hGH-CTP fails phase 3
FierceBiotech Opko’s shares are down more than 17% this morning on the news that its candidate for patients with a rare growth hormone deficiency missed its endpoint in a late-stage test. Share Facebook Twitter LinkedIn Email Print. Pfizer and drug partner Opko said … Growth hormone deficiency drug from OPKO and Pfizer fails study Mid-Day Market Update: Opko Health Drops After Disappointing Phase 3 Study of hGH-CTP; Cempra Shares Surge OPKO Health GHD Candidate Fails Phase III Trial |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.